6505--XOFIGO (Radium Ra-223)
Closed Pre-Solicitation Posted
- Solicitation number
- 36C25626Q0501
- Agency
-
Veterans Integrated Service Network 16
Veterans Health Administration, Department of Veterans Affairs
- Responses due
- Set-aside
- No set-aside
Opportunity facts
- NAICS code
- 325412 Pharmaceutical Preparation Manufacturing
- PSC
- 6505 Drugs And Biologicals
- Place of performance
- Michael E. DeBakey VA Medical Center 2002 Holcomb Blvd 77030, United States
- Points of contact
Notice details come from SAM.gov. Updated .
About this opportunity
The Department of Veterans Affairs Veterans Health Administration Veterans Integrated Service Network 16 is seeking sources for XOFIGO Isotope (Radium Ra-223), a nuclear medicine radiopharmaceutical used to treat castration-resistant prostate cancer with symptomatic bone metastases at the Michael E. DeBakey VA Medical Center in Houston, Texas. This is a Sources Sought Notice and Request for Information intended to identify potential vendors and establish procurement strategy prior to formal solicitation. Respondents must address their business size classification, compliance with the Non-Manufacturer Rule, authorized distributor status with manufacturer documentation, and provision of estimated market research pricing. Key qualifications include maintenance of licensed courier service for radioactive material transport in compliance with Department of Transportation and Nuclear Regulatory Commission regulations, personnel availability during standard business hours (Monday-Friday, 8:00 AM to 4:30 PM CST), and capability to provide calibration by or under supervision of a certified Nuclear Pharmacist within specified tolerances. Responses are due by March 17, 2026 at 3:00 PM Central Time and should be submitted via email to Frank Sanders (frank.sanders1@va.gov) in Microsoft Word format with standard formatting specifications.
This procurement carries no set-aside designation and will be competed on an unrestricted basis pending market research findings. The contract is structured as an Indefinite Delivery Indefinite Quantity (IDIQ) agreement with a performance period from October 1, 2025 through September 30, 2030, consisting of a base year plus four one-year option periods. The estimated annual requirement is 30 unit doses, with a minimum of 6 doses and maximum of 30 doses per fiscal year, and the base year total estimated cost is $375,679.18 based on Federal Supply Schedule pricing at approximately 4.9 patients per year receiving up to six doses each. The government will provide credit for up to 10 unadministered doses per fiscal year due to medical reasons within 30 business days. This RFI is preliminary and non-binding; responses will be used solely for market research purposes to inform the formal solicitation strategy, and interested parties should monitor the Federal Contract Opportunities website or GSA for the subsequent full solicitation.
Notice text
This is a source sought notice/request for information only. The responses to this posting will be used to establish the procurement strategy, for example, set-aside, sole source, unrestricted for a solicitation that VA intends to post in the near future. Please review the attached document(s) for more details on this requirement.
See attached document(s):
-36C25626Q0501 - Request for Information (RFI)
-Statement of Work (SOW)
DISCLAIMER: THIS IS A SOURCES SOUGHT NOTICE ONLY. THIS SYNOPSIS IS NOT A REQUEST FOR QUOTE, PROPOSAL, OR BID. This notice is not a solicitation as defined by FAR 2.101, therefore it shall not be construed as a commitment by the government to enter into a contract, nor does it restrict the government to an acquisition approach. All information contained in this Request for Information (RFI) is preliminary as well as subject to amendment and is in no way binding on the government. Information submitted in response to this notice is voluntary; the government will not pay for information requested nor will it compensate any respondent for any cost incurred in developing information provided to the government. The government is requesting that restrictive or proprietary markings not be used in response to this notice. If a solicitation is released, it will be synopsized in the Federal Contract Opportunities website or General Services Administration (GSA). It is the responsibility of the interested parties to monitor these sites for additional information pertaining to this RFI.
1. Title: XOFIGO Isotope (Radium Ra-223)
2. Purpose: The purpose of this RFI is to identify potential sources that will aid in defining the procurement strategy for example, set-aside, sole source, or unrestricted for a solicitation the VA intends on issuing shortly as follows:
The Michael E. DeBakey VA Medical Center (MEDVAMC) located in Houston, Texas has a requirement for XOFIGO Isotope (Radium Ra-223), items listed below:
Item#
Description/Part Number* Products
QTY
1.
6ML RADIUM RA 223DICHLORIDE INJ
XOFIGO
1 JB
The anticipated Small Business Administration (SBA) size standard for the North American Industry Classification System (NAICS) code is 325412 Pharmaceutical Preparation Manufacturing and a standard size of $19.0M. Product Supply Code (PSC) 6505 Drugs and Biologicals.
3. Responses Requested: The following questions must be answered in response to this RFI. Answers that are not provided shall be considered non-responsive to the RFI:
a. Are the requested items manufactured by a small or large business?
Vendor must attach documentation of this information to be viewed by the government to be considered as part of Market Research and responsiveness to this Sources Sought notice:
b. Is the potential vendor in compliance with the Non-Manufacturer Rule (NMR)?
Vendor must attach documentation of this to be viewed by the government to be considered as part of the Market Research and responsiveness to this Sources Sought notice:
c. Is the Vendor an authorized distributor with access to Original Equipment Manufacturer (OEM) parts which may be required in completion of this requirement? The VA does not accept grey market items; therefore, the Vendor must attach an authorized distribution letter as an approved and authorized vendor on OEM letterhead by the manufacturer as evidence of proof to be viewed by the government to be considered as part of the Market Research and responsiveness to this Sources Sought notice.
d. Name of potential Contractor that possesses the capability to fulfill this requirement. Contractors shall also provide the following:
Point(s) of contact name: ______________________________________
Address: ___________________________________________________
Telephone number: ___________________________________________
Email address: _______________________________________________
Company's business size: _______________________________________
UEI #: ______________________________
CAGE Code: _______________________________
e. Is your company considered a small business concern, SB, SDVOSB, VOSB, HUBZone, or 8A concern, with the requisite 325412 NAICS code?
Please provide proof of qualifications.
f. Is your company available under any Government Wide Agency Contract (GWAC), GSA Schedule, Federal Supply Schedule (FSS), Indefinite Delivery Indefinite Quantity (IDIQ), and/or Blanket Purchase Agreement (BPA)?
If so, please identify the contract number for the government to review as part of this Market Research.
4. Opportunity/Market Pricing: MEDVAMC is seeking information from potential vendors on their ability to provide the required items/equipment. THIS IS A SOURCES SOUGHT REQUEST FOR INFORMATION (RFI) ONLY. Small Business concerns are encouraged to provide responses to this RFI in order to assist the MEDVAMC in determining potential levels of competition and general market pricing available in the industry. Vendors are requested to submit estimated market research pricing along with their responses to the above. The estimated pricing will be considered when determining the procurement strategy for the forthcoming solicitation. Contractor shall provide answers to all questions requested and shall possess the ability to provide all requirements and objectives per the DRAFT STATEMENT OF WORK.
5. RFI responses are due by 15:00 pm Central Standard Time on March 17, 2026; size is limited to 8.5 x 11 inches, 12-point font, with 1-inch margins in Microsoft Word format via email to frank.sanders1@va.gov
The subject line shall read: RFI 36C25626Q0501- XOFIGO Isotope (Radium Ra-223)
NO SOLICITATION EXISTS AT THIS TIME.
There is no page limitation on subparagraphs 3(a) - 3(g). Please provide the information you deem relevant in order to respond to the specific inquiries of the RFI. Information provided will be used solely by MEDVAMC as Market Research and will not be released outside of the MEDVAMC Purchasing and Contracting Team.
6. Contact Information:
Frank Sanders
frank.sanders1@va.gov
See attached document: Statement of Work - Xofigo (Radium Ra-223).
Files
| File | Type | Posted |
|---|---|---|
| Xofigo SOW 2026 DRAFT.pdf | ||
| 36C25626Q0501.docx | DOCX document |
Similar open opportunities
| Opportunity | Agency | Set-aside | Responses due |
|---|---|---|---|
| 6505--FY27 Low Energy General Radiopharmaceuticals 36C25027Q0052 | Veterans Integrated Service Network 10 | No set-aside | |
| Sir - Sphere | Veterans Integrated Service Network 16 | No set-aside | |
| 6505--Sources Sought Notice - Ga68 Dotatate (NETSPOT) | Veterans Integrated Service Network 17 | No set-aside | |
| H365--460-27-1-132-0001 | SPE 49273 | VISN 4 Radiation Safety Officer (RSO) | NCO 4 Services 3 (VA-27-00003148) | Veterans Integrated Service Network 4 | Service-Disabled Veteran-Owned Small Business | |
| Nexodose dose monitor | Veterans Integrated Service Network 15 | No set-aside |
On GovTribe
Work this opportunity
- Track it in your pipeline
- Find teaming partners
- Similar opportunities
- Ask GovTribe AI about this opportunity